Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $14.1 million.

  • Agios Pharmaceuticals' Share-based Compensation rose 2954.23% to $14.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $52.6 million, marking a year-over-year increase of 2265.04%. This contributed to the annual value of $52.6 million for FY2025, which is 2265.04% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Share-based Compensation of $14.1 million as of Q4 2025, which was up 2954.23% from $12.4 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Share-based Compensation ranged from a high of $15.5 million in Q1 2022 and a low of $9.1 million during Q3 2023
  • For the 5-year period, Agios Pharmaceuticals' Share-based Compensation averaged around $12.1 million, with its median value being $11.6 million (2021).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Share-based Compensation crashed by 3462.93% in 2023, and later soared by 2954.23% in 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Share-based Compensation (Quarter) stood at $11.6 million in 2021, then dropped by 1.34% to $11.5 million in 2022, then increased by 20.49% to $13.8 million in 2023, then dropped by 21.07% to $10.9 million in 2024, then increased by 29.54% to $14.1 million in 2025.
  • Its last three reported values are $14.1 million in Q4 2025, $12.4 million for Q3 2025, and $14.7 million during Q2 2025.